With the start of its sec­ond clin­i­cal trial, NexImmune ex­pands de­vel­op­ment of its unique non-genetically engi­neered T cell immuno­therapies across a range of hema­to­logic malig­nan­cies

Gaithersburg, MD (Press Release) – NexImmune, a clin­i­cal-stage bio­technol­ogy com­pany devel­op­ing a port­folio of unique non-genetically-engi­neered T cell im­muno­therapies, an­nounced to­day that it has dosed the first patient in its Phase 1/2 clin­i­cal trial for NEXI-002. NEXI-002 is a patient-derived cel­lu­lar prod­uct that con­tains pop­u­la­tions of nat­u­rally-occurring CD8+ T cells directed against sev­er­al mul­ti­ple myeloma (MM)-specific an­ti­gen targets. It is the sec­ond clin­i­cal prod­uct NexImmune has gen­er­ated with its AIM nanoparticle tech­nology.

“While the pri­mary objective in this trial with NEXI-002 is to dem­onstrate safety and tol­er­a­bil­ity, we also hope to see ini­tial …

• IND clear­ance enables com­mence­ment of clin­i­cal trial to eval­u­ate NEXI-002 in multiple myeloma patients who have failed >3 pre­vi­ous lines of ther­apy
• FDA action rep­re­sents the Com­pany’s second IND clear­ance in 4Q2019 for its pipe­line of novel cellular ther­apy prod­ucts

Gaithersburg, MD (Press Release) – NexImmune, a clin­i­cal-stage bio­pharma­ceu­tical com­pany devel­op­ing novel immune-therapeutics based on a pro­pri­e­tary Artificial Immune Modulation (AIM) nanotechnology plat­form, has re­ceived IND clear­ance for the Com­pany’s second cellular ther­apy prod­uct. NEXI-002 is being devel­oped for the treat­ment of multiple myeloma patients that have failed at least three prior lines of ther­apy.

Scott P. Carmer, NexImmune’s Pres­i­dent and CEO, commented, “FDA clear­ance of our second IND this quarter marks another sig­nif­i­cant mile­stone for NexImmune and dem­onstrates our team’s focus and com­mitment to …